Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corsair Gaming Inc (CRSR) vs Quest Diagnostics Inc (DGX) Price & Performance

Corsair Gaming IncTrade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

Corsair Gaming Inc vs Quest Diagnostics Inc — how do they compare? Corsair Gaming Inc trades at $13.63 (market cap $1.42B), while Quest Diagnostics Inc trades at $230.97 (market cap $25.48B). The key difference: Quest Diagnostics Inc is far larger — about 17.9× Corsair Gaming Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Quest Diagnostics Inc for 56 Days on average.

CRSRDGX
Market Cap
$1.42B$25.48B
Volume
1,160,938941,866
Sector
TechnologyHealth
52-Week High
$14.35$247.45
52-Week Low
$4.58$173.49
Typical Hold Time
25 Days56 Days
Enterprise Value
$1.41B$31.23B
Dividend Yield
—1.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corsair Gaming Inc

Corsair Gaming (CRSR) trades at $13.63, up 0.29% with a bullish technical signal. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.23 exceeding expectations by 228%. Recent product launches like the VOXARA microphone and strategic acquisitions demonstrate growth initiatives. Financials show improving cash flow trends with projected 2026 operating cash flow of $106 million, though net income margins remain thin at 2.53%.

CRSR presents a mixed outlook with strong earnings momentum and product innovation offset by valuation concerns at 42x P/E. Analyst consensus is cautious with 64% hold ratings and $12.40 price target below current levels. Key risks include competitive gaming peripherals market and execution of growth strategy. The stock's near-term direction hinges on Q3 earnings delivery and sustained margin improvement.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.

The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRSR
100% Buy0% Sell
Avg holding period · 25 Days
DGX

No sentiment data available yet.

About Corsair Gaming Inc

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment

Read more on CRSR →

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX →